BRAF mutations
-
Pediatric low-grade glioma (pLGG) is essentially a single pathway disease, with most tumors driven by genomic alterations affecting the mitogen-activated protein kinase/ERK (MAPK) pathway, predominantly KIAA1549::BRAF fusions and BRAF V600E mutations. This makes pLGG an ideal candidate for MAPK pathway-targeted treatments.
11p vikoch 27-06-2024 1 1 Download
-
The Ras pathway genes KRAS, BRAF, or ERBBs have somatic mutations in ~ 60% of human colorectal carcinomas. At present, it is unknown whether the remaining cases lack mutations activating the Ras pathway or whether they have acquired mutations in genes hitherto unknown to belong to the pathway.
13p vibransone 28-03-2024 6 2 Download
-
Our review discuss (i) the findings from analyzed data that have examined KRAS, NRAS and BRAF mutations in patients with colorectal cancer (CRC) in North Africa and to compare its prevalence with that shown in other populations and (ii) the possible role of dietary and lifestyle factors with CRC risk.
14p vileonardodavinci 23-12-2023 4 2 Download
-
Patients with BRAF V600E mutated metastatic colorectal cancer (mCRC) have a poor prognosis. The introduction of BRAF targeted therapy with encorafenib and weekly administered cetuximab have shown improved survival with a median progression-free survival (PFS) of 4.3months.
6p vileonardodavinci 23-12-2023 5 2 Download
-
RAS mutations affect prognosis in patients with metastatic colorectal cancer (mCRC) and have been identified as strong negative predictive markers for anti-epidermal growth factor receptor monoclonal antibody (antiEGFR mAb) therapy, but many tumors containing wild-type RAS genes still do not respond to these therapies.
27p vileonardodavinci 23-12-2023 7 2 Download
-
To define the rate of BRAF V600E mutation in radioactive iodine (RAI) refractory papillary thyroid carcinoma (PTC). The correlation BRAF V600E mutation with some clinicopathologic features in RAI refractory PTC.
6p vispacex 13-11-2023 5 2 Download
-
The BRAF V600E mutation is one of the prognostic factors in thyroid carcinoma related to GLUT-1 expression which increases FDG uptake. In this study, we investigated the relationship between BRAF V600E mutation, clinicopathologic factors and 18F-fluoro-2-deoxyglucose (18F-FDG) avidity in radioiodine-refractory differentiated thyroid carcinoma (DTC).
8p visoros 01-11-2023 6 1 Download
-
Few highly accurate tests can diagnose central lymph node metastasis (CLNM) of papillary thyroid cancer (PTC). Genetic sequencing of tumor tissue has allowed the targeting of certain genetic variants for personalized cancer therapy development.
17p vischultz 20-10-2023 3 1 Download
-
Patients with V-Raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E-mutated advanced colorectal cancer (CRC) have a poor prognosis, and treatment options that can improve outcome are still under investigation.
11p vischultz 20-10-2023 3 1 Download
-
With more than 15,000 new cases /year in France and 2,000 deaths, cutaneous melanoma represents approximately 4% of incidental cancers and 1.2% of cancer related deaths. In locally advanced (stage III) or resect‑ able metastatic (stage IV) melanomas, medical adjuvant treatment is proposed and recent advances had shown the benefit of anti-PD1/PDL1 and anti-CTLA4 immunotherapy as well as anti-BRAF and anti-MEK targeted therapy in BRAF V600 mutated tumors.
11p visharma 20-10-2023 4 2 Download
-
The detection of BRAF V600E immunoexpression in papillary thyroid carcinoma (PTC) is extremely important because of its association with poor prognosis. Is poor prognosis really associated with all histological variants of thyroid papillary carcinoma? To contribute to this elucidation, using the BRAF V600E mutation-specific antibody, the present study was performed to determine the association between BRAF V600E immunoexpression and clinicopathological variant groups of PTC.
6p vimalfoy 08-02-2023 3 2 Download
-
Virtually all metastatic patients with metastatic melanoma who progress after initial treatment with PD-1 or CTLA-4 directed antibodies will die of their disease. Salvage options are urgently needed. It is theoretically attractive to combine immunotherapy with targeted agents in progressing patients with BRAF mutation positive melanoma, but the toxicity of combined treatment has proven challenging.
12p vimahuateng 26-11-2021 5 0 Download
-
Mutations involving BRAF and TERT are important predictors of disease severity in thyroid cancer, but molecular testing is limited by cost and lack of adequate tissue sample. This study aimed to assess the utility of BRAFV600E and TERT testing using droplet digital PCR (ddPCR) as a diagnostic and prognostic tool for thyroid fine needle aspirate biopsy (FNAB).
9p vimahuateng 26-11-2021 8 1 Download
-
Outcomes are poorer in metastatic colorectal cancer (mCRC) patients with BRAF V600E mutations than those without it, but the effect of these mutations on treatment response is unclear. This real-world study assessed the effects of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF V600-mutated mCRC.
10p vianrose2711 27-04-2021 8 1 Download
-
While molecularly targeted therapies and immune checkpoint inhibitors have improved the prognosis of advanced melanoma, biomarkers are required to monitor drug responses. Circulating tumor cells (CTCs) are released from primary and/or metastatic tumors into the peripheral blood.
8p vianrose2711 27-04-2021 52 1 Download
-
KRAS is an EGFR effector in the RAS/RAF/ERK cascade that is mutated in about 40% of metastatic colorectal cancer (mCRC). Activating mutations in codons 12 and 13 of the KRAS gene are the only established negative predictors of response to anti-EGFR therapy and patients whose tumors harbor such mutations are not candidates for therapy.
10p vijisoo2711 29-09-2020 7 1 Download
-
Gene silencing of the repair genes MLH1 and MGMT was shown to be a mechanism underlying the development of microsatellite instability (MSI), a phenotype frequently associated with various human malignancies. Recently, aberrant methylation of MLH1, MGMT and MSI were shown to be associated with mutations in genes such as BRAF, RAS and IDH1 in colon and brain tumours.
7p vijisoo2711 29-09-2020 12 1 Download
-
Conventional therapeutic agents are largely unsatisfactory into the treatment of malignant melanoma. Recently, an innovative approach based on inhibitors of the mutated BRAF gene (which represents the most prevalent alteration in melanoma patients) appears very promising from the clinical point of view.
3p vijisoo2711 29-09-2020 15 1 Download
-
The mutation status of the BRAF and KRAS genes has been proposed as prognostic biomarker in colorectal cancer. Of them, only the BRAF V600E mutation has been validated independently as prognostic for overall survival and survival after relapse, while the prognostic value of KRAS mutation is still unclear.
7p vijennie2711 29-09-2020 13 1 Download
-
Knowledge about tumour gene mutation status is essential for the treatment of increasing numbers of cancer patients, and testing quality has a major impact on treatment response and cost. In 2012, 4,629 tests for BRAF p.V600 were performed in France, in patients with melanomas.
6p vijennie2711 29-09-2020 8 1 Download